Key Takeaways VKTX enrolled about 180 adults in a phase I maintenance study evaluating VK2735 after initial weight loss.VKTX is testing several SC and oral dosing regimens to assess safety, tolerability and pharmacokinetics.VKTX is also evaluating VK2735 in two phase III studies, with obesity data from both studies expected in 2027.Viking Therapeutics (VKTX) announced that it has completed enrolling patients in its exploratory maintenance dosing study of VK2735, the company's dual agonist of the GLP-1 and G ...